Literature DB >> 22244414

Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.

Adrianne L Myers1, W Shannon Orr, Jason W Denbo, Catherine Y Ng, Junfang Zhou, Yunyu Spence, Jianrong Wu, Andrew M Davidoff.   

Abstract

PURPOSE: Rapamycin inhibits vascular endothelial growth factor expression. Vascular endothelial growth factor is a tumor-elaborated protein that stimulates neovascularization. This inhibition can cause transient "normalization" of the generally dysfunctional tumor vasculature, resulting in improved tumor perfusion and oxygenation. We hypothesized that this may potentiate the antitumor effects of adjuvant ionizing radiation.
METHODS: Mice bearing orthotopic Rh30 alveolar rhabdomyosarcomas were treated with rapamycin (5 mg/kg intraperitoneally daily ×5). Tumors were then evaluated for changes in intratumoral oxygenation, perfusion, vessel permeability, and microvessel density. Additional tumor-bearing mice were treated with 5 doses of rapamycin, irradiation (4 Gy), or 5 doses of rapamycin with irradiation administered on the first or sixth day of rapamycin treatment.
RESULTS: Although tumor vessel permeability changed only minimally, microvessel density decreased (3153 ± 932 vs 20,477 ± 3717.9 pixels per high-power field), whereas intratumoral oxygenation increased significantly (0.0385 ± 0.0141 vs 0.0043 ± 0.0023 mm Hg/mm(3)) after 5 doses of rapamycin. Contrast-enhanced ultrasound demonstrated a significantly increased rate of change of signal intensity after 5 days of rapamycin, suggesting improved intratumoral perfusion. Tumor volume 14 days after treatment was smallest in mice treated with the combination of rapamycin given before irradiation.
CONCLUSION: Combination therapy with rapamycin given before irradiation to normalize the tumor vasculature, thereby improving tumor oxygenation, increased the sensitivity of alveolar rhabdomyosarcoma xenografts to adjuvant irradiation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244414      PMCID: PMC3259455          DOI: 10.1016/j.jpedsurg.2011.10.034

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  11 in total

1.  Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US.

Authors:  M Beth McCarville; Christian J Streck; Paxton V Dickson; Chin-Shang Li; Amit C Nathwani; Andrew M Davidoff
Journal:  Radiology       Date:  2006-07       Impact factor: 11.105

2.  Statistical aspects of the independent joint action of poisons, particularly insecticides; the toxicity of a mixture of poisons.

Authors:  R L PLACKETT; P S HEWLETT
Journal:  Ann Appl Biol       Date:  1948-09       Impact factor: 2.750

3.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

4.  Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model.

Authors:  William W Spurbeck; Catherine Y C Ng; Ted S Strom; Elio F Vanin; Andrew M Davidoff
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

Review 6.  Pediatric soft tissue sarcomas.

Authors:  David M Loeb; Katherine Thornton; Ori Shokek
Journal:  Surg Clin North Am       Date:  2008-06       Impact factor: 2.741

7.  Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.

Authors:  Philipp C Manegold; Carmen Paringer; Ulrike Kulka; Klaus Krimmel; Martin E Eichhorn; Ralf Wilkowski; Karl-Walter Jauch; Markus Guba; Christiane J Bruns
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

8.  A new glioma model in rat: the C6 spheroid implantation technique permeability and vascular characterization.

Authors:  C L Farrell; P A Stewart; R F Del Maestro
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Authors:  Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

Authors:  R B Raney; H M Maurer; J R Anderson; R J Andrassy; S S Donaldson; S J Qualman; M D Wharam; E S Wiener; W M Crist
Journal:  Sarcoma       Date:  2001
View more
  3 in total

Review 1.  Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives.

Authors:  Seraina Faes; Nicolas Demartines; Olivier Dormond
Journal:  Front Cell Dev Biol       Date:  2021-03-15

2.  Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells.

Authors:  Zhi-Jun Dai; Jie Gao; Hua-Feng Kang; Yu-Guang Ma; Xiao-Bin Ma; Wang-Feng Lu; Shuai Lin; Hong-Bing Ma; Xi-Jing Wang; Wen-Ying Wu
Journal:  Drug Des Devel Ther       Date:  2013-03-19       Impact factor: 4.162

Review 3.  Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.

Authors:  Seraina Faes; Tania Santoro; Nicolas Demartines; Olivier Dormond
Journal:  Cancers (Basel)       Date:  2017-11-01       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.